Catabasis Pharmaceuticals to Present at 2021 Wedbush PacGrow Healthcare Conference
Get Alerts CATB Hot Sheet
Join SI Premium – FREE
BOSTON--(BUSINESS WIRE)-- Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will be presenting during a fireside chat at the upcoming virtual Wedbush PacGrow Healthcare Conference on Tuesday, August 10th, 2021 at 8:35am ET. The session entitled “HAE There- Development Landscape in Hereditary Angioedema (HAE)” will include an overview of the HAE treatment landscape, information about Catabasis’s lead program QLS-215, and a Q&A session.
A webcast of the presentation will be available at the following link: https://wsw.com/webcast/wedbush39/panel11/2571740, and will also be available in the investors section of the Company’s website, www.catabasis.com, and will be archived for 30 days following the presentation.
About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope with life-changing therapies to patients and families affected by rare and niche diseases. Our lead program, QLS-215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210804005076/en/
Investor relations:
Andrea Matthews
[email protected]
Media:
Elizabeth Higgins
[email protected]
Source: Catabasis Pharmaceuticals, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Guidewire Jasper Release Boosts Commercial Lines Agility for P&C Insurers and Strengthens Functionality Across Entire Product Portfolio
- Announcement of change in the total number of votes in AB SKF
- Finally, A Concours in Scandinavia: In Partnership with BMW, Koenigsegg, and MOTIKON
Create E-mail Alert Related Categories
Business Wire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!